A Phase 3 Study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension 0.05%) to Treat Inflammation and Pain after Cataract Surgery

clobetasol nanosuspension (APP13007) - Formosa Labs, AimMax Therap

Michael S Korenfeld; Thomas Walters; Joseph Martel; Derek J. Nunez; Laurene Wang

Mar 24, 2023